ABSTRACT
PURPOSE: An increasing number of patients with Duchenne muscular dystrophy (DMD) now have access to improved standard of care and disease modifying treatments, which improve the clinical course of DMD and extend life expectancy beyond 30 years of age. A key issue for adolescent DMD patients is the transition from paediatric- to adult-oriented healthcare. Adolescents and adults with DMD have unique but highly complex healthcare needs associated with long-term steroid use, orthopaedic, respiratory, cardiac, psychological, and gastrointestinal problems meaning that a comprehensive transition process is required. A sub-optimal transition into adult care can have disruptive and deleterious consequences for a patient's long-term care. This paper details the results of a consensus amongst clinicians on transitioning adolescent DMD patients from paediatric to adult neurologists that can act as a guide to best practice to ensure patients have continuous comprehensive care at every stage of their journey. METHODS: The consensus was derived using the Delphi methodology. Fifty-three statements were developed by a Steering Group (the authors of this paper) covering seven topics: Define the goals of transition, Preparing the patient, carers/parents and the adult centre, The transition process at the paediatric centre, The multidisciplinary transition summary - Principles, The multidisciplinary transition summary - Content, First visit in the adult centre, Evaluation of transition. The statements were shared with paediatric and adult neurologists across Central Eastern Europe (CEE) as a survey requesting their level of agreement with each statement. RESULTS: Data from 60 responders (54 full responses and six partial responses) were included in the data set analysis. A consensus was agreed across 100% of the statements. CONCLUSIONS: It is hoped that the findings of this survey which sets out agreed best practice statements, and the transfer template documents developed, will be widely used and so facilitate an effective transition from paediatric to adult care for adolescents with DMD.
Subject(s)
Delphi Technique , Muscular Dystrophy, Duchenne , Humans , Muscular Dystrophy, Duchenne/therapy , Adolescent , Israel , Neurologists , Greece , Adult , Transition to Adult Care , Consensus , Male , Child , Female , EuropeABSTRACT
OBJECTIVE: To evaluate the outcome of recombinant human Growth Hormone (rhGH) therapy in patients with Duchene Muscular Dystrophy (DMD) and glucocorticoid treatment with compromised growth. DESIGN: Four DMD patients on Deflzacort 0.6-0.85 mg/kg/day or prednisolone 0.625 mg/kg/day recieved rhGH (0.24 mg/kg/week) for 6-18 months. Primary outcomes were Growth velocity and Height for age Z-scores (Height SD). RESULTS: Growth velocity increased from 0 to 3.25 cm/year prior to GH therapy to 3.3-7.8 cm/year over a period of 6-18 months. The typical Height SD decline in DMD was reversed in two patients and blunted in one. No adverse events or deterioration in cardiac or respiratory parameters were associated with the rhGH treatment. CONCLUSIONS: rhGH appears to be safe and efficient in promoting growth of patients with glucocorticoid induced growth failure in DMD.
Subject(s)
Dwarfism , Human Growth Hormone , Muscular Dystrophy, Duchenne , Child , Humans , Glucocorticoids/adverse effects , Human Growth Hormone/adverse effects , Muscular Dystrophy, Duchenne/drug therapy , Growth Hormone , Prednisolone/adverse effects , Body HeightABSTRACT
Duchene muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are genetic neuromuscular disorders that affect skeletal and cardiac muscle resulting from mutations in the dystrophin gene (DMD), coding for dystrophin protein. Read-through therapies hold great promise for the treatment of genetic diseases harboring nonsense mutations, such as DMD/BMD, as they enable a complete translation of the affected mRNA. However, to date, most read-through drugs have not achieved a cure for patients. One possible explanation for the limitation of these therapies for DMD/BMD is that they rely on the presence of mutant dystrophin mRNAs. However, the mutant mRNAs containing premature termination codons are identified by the cellular surveillance mechanism, the nonsense-mediated mRNA decay (NMD) process, and are degraded. Here, we show that the combination of read-through drugs together with known NMD inhibitors have a synergistic effect on the levels of nonsense-containing mRNAs, among them the mutant dystrophin mRNA. This synergistic effect may enhance read-through therapies' efficacy and improve the current treatment for patients.
Subject(s)
Muscular Dystrophy, Duchenne , Humans , Muscular Dystrophy, Duchenne/drug therapy , Muscular Dystrophy, Duchenne/genetics , Muscular Dystrophy, Duchenne/metabolism , Dystrophin/genetics , Dystrophin/metabolism , Codon, Terminator/genetics , Nonsense Mediated mRNA Decay , MutationABSTRACT
The circadian clock, which drives a wide range of bodily rhythms in synchrony with the day-night cycle, is based on a molecular oscillator that ticks with a period of approximately 24 h. Timed proteasomal degradation of clock components is central to the fine-tuning of the oscillator's period. FBXL3 is a protein that functions as a substrate-recognition factor in the E3 ubiquitin ligase complex, and was originally shown in mice to mediate degradation of CRY proteins and thus contribute to the mammalian circadian clock mechanism. By exome sequencing, we have identified a FBXL3 mutation in patients with syndromic developmental delay accompanied by morphological abnormalities and intellectual disability, albeit with a normal sleep pattern. We have investigated the function of FBXL3 in the zebrafish, an excellent model to study both vertebrate development and circadian clock function and, like humans, a diurnal species. Loss of fbxl3a function in zebrafish led to disruption of circadian rhythms of promoter activity and mRNA expression as well as locomotor activity and sleep-wake cycles. However, unlike humans, no morphological effects were evident. These findings point to an evolutionary conserved role for FBXL3 in the circadian clock system across vertebrates and to the acquisition of developmental roles in humans.
Subject(s)
Circadian Clocks/genetics , F-Box Proteins/genetics , Genetic Diseases, Inborn/genetics , Rare Diseases/genetics , Zebrafish/genetics , Animals , Circadian Rhythm/genetics , Humans , Intellectual Disability/genetics , Mammals/genetics , Models, Animal , Mutation/geneticsABSTRACT
Patients having Duchenne muscular dystrophy (DMD) are currently being treated with corticosteroids, which slow down disease progression at the expense of serious adverse effects. Tamoxifen is a pro-drug some of whose metabolites interact with the nuclear estrogen receptor, leading to anti-fibrotic and muscle-protective effects as has been demonstrated in a murine model of DMD. Here we report the results from a monocentric single arm prospective study in 13 ambulant boys aged 6-14 years with genetically confirmed DMD, aimed to assess the safety of tamoxifen and its impact on disease progression. Boys were treated for up to 3 years with 20â¯mg/day of oral tamoxifen, in addition to their ongoing corticosteroid treatment. For 8 of these patients, outcome was compared to an age- and performance-matched 12-month natural history dataset. The primary end point was the 6-minute walk test. Secondary end points were the NorthStar assessment, timed function tests, pulmonary function, the biomarker creatine phosphokinase and adverse effects. No adverse effects were noticed other than mild gynecomastia in 4 boys. Tamoxifen-treated patients retained motor and respiratory function, compared with a significant deterioration of age-matched historical control patients receiving corticosteroids only. These encouraging findings warrant a larger clinical trial to substantiate the use of tamoxifen in Duchenne muscular dystrophy.
Subject(s)
Muscular Dystrophy, Duchenne/drug therapy , Selective Estrogen Receptor Modulators/therapeutic use , Tamoxifen/therapeutic use , Adolescent , Adrenal Cortex Hormones/therapeutic use , Child , Disease Progression , Humans , Israel , Male , Motor Activity/drug effects , Prospective Studies , Treatment Outcome , Walk TestABSTRACT
Liver damage is typically inferred from serum measurements of cytoplasmic liver enzymes. DNA molecules released from dying hepatocytes are an alternative biomarker, unexplored so far, potentially allowing for quantitative assessment of liver cell death. Here we describe a method for detecting acute hepatocyte death, based on quantification of circulating, cell-free DNA (cfDNA) fragments carrying hepatocyte-specific methylation patterns. We identified 3 genomic loci that are unmethylated specifically in hepatocytes, and used bisulfite conversion, PCR, and massively parallel sequencing to quantify the concentration of hepatocyte-derived DNA in mixed samples. Healthy donors had, on average, 30 hepatocyte genomes/ml plasma, reflective of basal cell turnover in the liver. We identified elevations of hepatocyte cfDNA in patients shortly after liver transplantation, during acute rejection of an established liver transplant, and also in healthy individuals after partial hepatectomy. Furthermore, patients with sepsis had high levels of hepatocyte cfDNA, which correlated with levels of liver enzymes aspartate aminotransferase (AST) and alanine aminotransferase (ALT). Duchenne muscular dystrophy patients, in which elevated AST and ALT derive from damaged muscle rather than liver, did not have elevated hepatocyte cfDNA. We conclude that measurements of hepatocyte-derived cfDNA can provide specific and sensitive information on hepatocyte death, for monitoring human liver dynamics, disease, and toxicity.
Subject(s)
Biomarkers/blood , Cell-Free Nucleic Acids/blood , Hepatocytes/metabolism , Liver Diseases/blood , Liver Diseases/diagnosis , Liver/metabolism , Alanine Transaminase/analysis , Aspartate Aminotransferases/analysis , Blood Proteins/genetics , Cell Death , DNA Methylation , Glycoproteins/genetics , Hepatectomy , High-Throughput Nucleotide Sequencing , Humans , Liver/enzymology , Liver Transplantation , Proteinase Inhibitory Proteins, Secretory/genetics , Receptor, IGF Type 2/genetics , Sensitivity and SpecificityABSTRACT
Rearrangement of the actin cytoskeleton is controlled by RhoGTPases which are activated by RhoGEFs. We identified homozygosity for Arg204Trp mutation in the Rho guanidine exchange factor (RhoGEF) PLEKHG2 gene in five patients with profound mental retardation, dystonia, postnatal microcephaly, and distinct neuroimaging pattern. The activity of the mutant PLEKHG2 was significantly decreased, both in basal state and when Gßγ- or lysophosphatidic acid (LPA)-stimulated. SDF1a-stimulated actin polymerization was significantly impaired in patient cells, and this abnormality was duplicated in control cells when PLEKHG2 expression was downregulated. These results underscore the role of PLEKHG2 in actin polymerization and delineate the clinical and radiological findings in PLEKHG2 deficiency.
Subject(s)
Actins/metabolism , Dystonia/genetics , Guanine Nucleotide Exchange Factors/genetics , Microcephaly/genetics , Arabs , Consanguinity , Dystonia/complications , Family , Female , HEK293 Cells , Humans , Male , Microcephaly/complications , Middle East , Mutation, Missense , Pedigree , Protein Multimerization/geneticsABSTRACT
The exosome is a multi-protein complex, required for the degradation of AU-rich element (ARE) containing messenger RNAs (mRNAs). EXOSC8 is an essential protein of the exosome core, as its depletion causes a severe growth defect in yeast. Here we show that homozygous missense mutations in EXOSC8 cause progressive and lethal neurological disease in 22 infants from three independent pedigrees. Affected individuals have cerebellar and corpus callosum hypoplasia, abnormal myelination of the central nervous system or spinal motor neuron disease. Experimental downregulation of EXOSC8 in human oligodendroglia cells and in zebrafish induce a specific increase in ARE mRNAs encoding myelin proteins, showing that the imbalanced supply of myelin proteins causes the disruption of myelin, and explaining the clinical presentation. These findings show the central role of the exosomal pathway in neurodegenerative disease.
Subject(s)
Agenesis of Corpus Callosum/genetics , Cerebellum/abnormalities , Exosome Multienzyme Ribonuclease Complex/genetics , Hereditary Central Nervous System Demyelinating Diseases/genetics , Nervous System Malformations/genetics , RNA-Binding Proteins/genetics , Spinal Muscular Atrophies of Childhood/genetics , Amino Acid Sequence , Animals , Cerebellum/pathology , Cerebral Cortex/pathology , Developmental Disabilities/genetics , Developmental Disabilities/pathology , Female , Fungal Proteins/metabolism , Gene Expression , Gene Knockdown Techniques , Hereditary Central Nervous System Demyelinating Diseases/pathology , Homozygote , Humans , Infant , Male , Molecular Sequence Data , Nervous System Malformations/pathology , Sequence Analysis, DNA , Syndrome , ZebrafishABSTRACT
BACKGROUND: Hereditary spastic paraparesis (HSP) (syn. Hereditary spastic paraplegia, SPG) are a group of genetic disorders characterised by spasticity of the lower limbs due to pyramidal tract dysfunction. Nearly 60 disease loci have been identified, which include mutations in two genes (KIF5A and KIF1A) that encode motor proteins of the kinesin superfamily. Here we report a novel genetic defect in KIF1C of patients with spastic paraparesis and cerebellar dysfunction in two consanguineous families of Palestinian and Moroccan ancestry. METHODS AND RESULTS: We performed autozygosity mapping in a Palestinian and classic linkage analysis in a Moroccan family and found a locus on chromosome 17 that had previously been associated with spastic ataxia type 2 (SPAX2, OMIM %611302). Whole-exome sequencing revealed two homozygous mutations in KIF1C that were absent among controls: a nonsense mutation (c.2191C>T, p.Arg731*) that segregated with the disease phenotype in the Palestinian kindred resulted in the entire absence of KIF1C protein from the patient's fibroblasts, and a missense variant (c.505C>T, p.Arg169Trp) affecting a conserved amino acid of the motor domain that was found in the Moroccan kindred. CONCLUSIONS: Kinesin genes encode a family of cargo/motor proteins and are known to cause HSP if mutated. Here we identified nonsense and missense mutations in a further member of this protein family. The KIF1C mutation is associated with a HSP subtype (SPAX2/SAX2) that combines spastic paraplegia and weakness with cerebellar dysfunction.
Subject(s)
Cerebellar Diseases/genetics , Kinesins/genetics , Paraparesis, Spastic/genetics , Adolescent , Amino Acid Sequence , Base Sequence , Child , Child, Preschool , Consanguinity , DNA Mutational Analysis , Female , Genetic Association Studies , Genetic Linkage , HEK293 Cells , Humans , Infant , Male , Molecular Sequence Data , Pedigree , Polymorphism, Single Nucleotide , Young AdultABSTRACT
We describe an autosomal recessive heterogeneous congenital myopathy in a large consanguineous family. The disease is characterized by variable severity, progressive course in 3 of 4 patients, myopathic face without ophthalmoplegia and proximal muscle weakness. Absence of cores was noted in all patients. Genome wide linkage analysis revealed a single locus on chromosome 19q13 with Zmaxâ=â3.86 at θâ=â0.0 and homozygosity of the polymorphic markers at this locus in patients. Direct sequencing of the main candidate gene within the candidate region, RYR1, was performed. A novel homozygous A to G nucleotide substitution (p.Y3016C) within exon 60 of the RYR1 gene was found in patients. ARMS PCR was used to screen for the mutation in all available family members and in an additional 150 healthy individuals. This procedure confirmed sequence analysis and did not reveal the A to G mutation (p.Y3016C) in 300 chromosomes from healthy individuals. Functional analysis on EBV immortalized cell lines showed no effect of the mutation on RyR1 pharmacological activation or the content of intracellular Ca(2+) stores. Western blot analysis demonstrated a significant reduction of the RyR1 protein in the patient's muscle concomitant with a reduction of the DHPRα1.1 protein. This novel mutation resulting in RyR1 protein decrease causes heterogeneous clinical presentation, including slow progression course and absence of centrally localized cores on muscle biopsy. We suggest that RYR1 related myopathy should be considered in a wide variety of clinical and pathological presentation in childhood myopathies.
Subject(s)
Muscle, Skeletal/metabolism , Muscle, Skeletal/pathology , Mutation/genetics , Ryanodine Receptor Calcium Release Channel/genetics , Adolescent , Adult , Blotting, Western , Calcium/metabolism , Cell Line , Child , Child, Preschool , Exons/genetics , Female , Genetic Linkage/genetics , Genome-Wide Association Study , Humans , Infant , Infant, Newborn , Male , Young AdultABSTRACT
PURPOSE: The molecular etiology of primary intractable epilepsy in infancy is largely unknown. We studied a nonconsanguineous Moroccan-Jewish family, where three of their seven children presented with intractable seizures and died at 18-36 months. METHODS: Homozygous regions were searched using 250 K DNA single nucleotide polymorphism (SNP) array. The sequence of 50 Mb exome of a single patient was determined using SOLiD 5500XL deep sequencing analyzer. KEY FINDINGS: A single homozygous 11.3 Mb genomic region on chromosome 6 was linked to the disease in this family. This region contained 110 genes encoding a total of 1,000 exons. Whole exome sequencing revealed a single pathogenic homozygous variant within the critical region. The mutation, Phe229Leu in the EFHC1 gene was previously shown, in a carrier state, to be associated with juvenile myoclonic epilepsy. SIGNIFICANCE: Although heterozygosity for the Phe229Leu mutation is known to be associated with a relatively benign form of epilepsy in adolescence; homozygosity for the same mutation is associated with lethal epilepsy of infancy. Given the considerable carrier rate of this mutation worldwide, the sequence of the EFHC1 gene should be determined in all patients with primary intractable epilepsy in infancy.
Subject(s)
Calcium-Binding Proteins/genetics , Epilepsy/genetics , Polymorphism, Single Nucleotide/genetics , Child, Preschool , Exome/genetics , Fatal Outcome , Homozygote , Humans , Infant , Infant, Newborn , Male , PedigreeABSTRACT
Whole exome sequencing has become a pivotal methodology for rapid and cost-effective detection of pathogenic variations in Mendelian disorders. A major challenge of this approach is determining the causative mutation from a substantial number of bystander variations that do not play any role in the disease etiology. Current strategies to analyze variations have mainly relied on genetic and functional arguments such as mode of inheritance, conservation, and loss of function prediction. Here, we demonstrate that disease-network analysis provides an additional layer of information to stratify variations even in the presence of incomplete sequencing coverage, a known limitation of exome sequencing. We studied a case of Hereditary Spastic Paraparesis (HSP) in a single inbred Palestinian family. HSP is a group of neuropathological disorders that are characterized by abnormal gait and spasticity of the lower limbs. Forty-five loci have been associated with HSP and lesions in 20 genes have been documented to induce the disorder. We used whole exome sequencing and homozygosity mapping to create a list of possible candidates. After exhausting the genetic and functional arguments, we stratified the remaining candidates according to their similarity to the previously known disease genes. Our analysis implicated the causative mutation in the motor domain of KIF1A, a gene that has not yet associated with HSP, which functions in anterograde axonal transportation. Our strategy can be useful for a large class of disorders that are characterized by locus heterogeneity, particularly when studying disorders in single families.
Subject(s)
Kinesins/genetics , Sequence Analysis, DNA/methods , Spastic Paraplegia, Hereditary/genetics , Adolescent , Adult , Amino Acid Sequence , Databases, Genetic , Exons/genetics , Genotype , Homozygote , Humans , Male , Models, Molecular , Mutation , Pedigree , Phenotype , Polymorphism, Single Nucleotide , Spastic Paraplegia, Hereditary/pathology , Young AdultABSTRACT
UNLABELLED: Referral letters to pediatric emergency departments (ED) may be an important source of information available to the emergency department staff. This mode of communication has been subject to relatively few studies. OBJECTIVES: Our objective was to canvass the expectations of ED physicians from referral letters and contrast these expectations with the actual content of referral letters. METHODS: A questionnaire containing different items of information that may appear in referral letters was distributed to ED pediatricians. The physicians scored these items and were asked to add other items that should, in their opinion, appear in referral letters. Scores given to the items ranged from "not important" (score = 1) to "very important" (score = 5). Information regarding the physician's experience in the field of pediatrics was obtained. Subsequently, sequential referral letters were collected from a pediatric ER. These letters were analyzed with respect to the items scored in the first part of the study. Letters were stratified to handwritten and form letters, and by language. RESULTS: A total of 21 physicians participated in the study. The mostly valued pieces of information were clinical information (principal complaint, physical examination prior to referral, past medical history) as well as demographic data and information regarding the referring physician. Lower scores were given to items regarding socioeconomic background of the patient, immunizations and tentative diagnosis. A total of 299 letters were collected. Items missing in more than 50 percent of letters were: socioeconomic background, family medical history, allergies, immunizations, current medications, referring physician's phone number, past medical history. Form letters contained more information than handwritten letters. CONCLUSION: Referral letters to pediatric ED's do not live up to the expectations of the receiving physicians. Specific expectations from, and shortcomings of letters may be pinpointed and addressed.